• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    7/1/26 4:01:27 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FRMM alert in real time by email
    false 0001690080 0001690080 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): June 30, 2026

     

    Forum Markets, Incorporated

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38105   90-1890354
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2875 South Ocean Blvd, Suite 100
    Palm Beach, FL
      33480
    (Address of Principal Executive Offices)   (Zip Code)

     

    (650) 507-0669

    (Registrant's telephone number, including area code)

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   FRMM   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On June 30, 2026, Forum Markets, Inc. (the “Company”) and Zippy, Inc. (“Zippy”) entered into Side Letter Amendment No. 2 (the “Second Amendment”) to the Series B-3 Preferred Stock Purchase Agreement, dated as of December 9, 2025, as previously amended by the Side Letter Amendment dated March 25, 2026 (as so amended, the “Zippy Purchase Agreement”). As further detailed below, the Company and Zippy entered into the Second Amendment in furtherance of the parties' ongoing strategic partnership, to provide both parties with greater flexibility with respect to the timing and measurement of the Final Make Whole Amount (as defined below) and to spread the risk associated with the performance of the Company’s common stock by replacing the single true-up determination date with three separate measurement and payment dates.

     

    Under the Zippy Purchase Agreement as previously in effect, the Company was obligated to pay Zippy a single “Final Make Whole Amount,” measured as of a single true-up determination date of June 30, 2026 (the “Original True-Up Determination Date”), equal to the difference, if any, between the value of the Retained Stock (as defined in the Zippy Purchase Agreement) based on a per share price of $10.50 and the value of the Retained Stock based on the volume-weighted average price of the Company’s common stock for the ten (10) trading days prior to that date.

     

    The Second Amendment amends Section 6.2 of the Zippy Purchase Agreement to replace the single Original True-Up Determination Date with a trifurcated true-up framework consisting of three separate measurement and payment dates—a first true-up date of July 31, 2026, a second true-up date of September 30, 2026, and a third true-up date of December 31, 2026—each with its own independent make-whole calculation and payment obligation. During a corresponding sell period to each true-up date, Zippy may sell, in its sole discretion, up to a designated number of shares of the Company’s common stock (up to 285,714 shares per period), and any eligible shares not sold during a prior period that are carried forward and become eligible for sale in the following period(s). After each true-up date, Zippy is required to deliver to the Company a written settlement statement, and the Company is required to pay the applicable make-whole amount, if any, in cash by wire transfer of immediately available funds within ten (10) business days after its receipt of the settlement statement (and in no event later than ten (10) business days after the applicable true-up date).

     

    For each of the first two sell periods, the applicable make-whole amount equals the number of eligible shares actually sold during that period multiplied by the $10.50 per share price, less the aggregate gross proceeds Zippy received from those sales; no amount is payable with respect to unsold shares, and the make-whole amount is zero if gross proceeds equal or exceed the guaranteed amount. For the third true-up period, the make-whole amount is calculated both with respect to shares sold during the third sell period (measured against gross proceeds) and with respect to shares retained by Zippy through December 31, 2026 (measured against the volume-weighted average price of the Company’s common stock for the ten (10) trading days prior to December 31, 2026), with Zippy able to elect sale or retention treatment for shares in any combination in its sole discretion. The Second Amendment provides that the three make-whole amounts are calculated on distinct, non-overlapping pools of shares so that no double recovery occurs, and that the Company’s aggregate make-whole obligation will not exceed the amount necessary for Zippy to receive, in the aggregate, proceeds equivalent to $10.50 per share for each share originally comprising the stock consideration.

     

    The Second Amendment also makes certain conforming changes, including (i) providing that the Company’s obligation to pay the Final Make Whole Amount for purposes of the forfeiture provisions of the Zippy Purchase Agreement will be deemed satisfied if the Company timely pays each of the three true-up make-whole amounts, while confirming that the Company’s failure to timely pay any such amount constitutes a failure to timely pay a cash amount for purposes of the “ETHZ Forfeiture Event” definition under the Zippy Purchase Agreement, and (ii) extending Zippy’s monthly stock transaction reporting covenant through December 31, 2026 and applying it separately with respect to each true-up determination date.

     

    The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    1

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Side Letter Amendment No. 2 to Series B-3 Preferred Stock Purchase Agreement, dated as of June 30, 2026, by and between Forum Markets, Inc. and Zippy, Inc.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      FORUM MARKETS, INCORPORATED
         
    Date: July 1, 2026 By: /s/ McAndrew Rudisill
      Name: McAndrew Rudisill
      Title: Chief Executive Officer

     

     

    3

     

    Get the next $FRMM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRMM

    DatePrice TargetRatingAnalyst
    4/7/2026$5.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $FRMM
    SEC Filings

    View All

    Forum Markets Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FORUM MARKETS Inc (0001690080) (Filer)

    7/16/26 8:00:14 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Forum Markets Incorporated

    DEFA14A - FORUM MARKETS Inc (0001690080) (Filer)

    7/9/26 4:02:18 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Forum Markets Incorporated

    DEF 14A - FORUM MARKETS Inc (0001690080) (Filer)

    7/8/26 4:11:15 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Forum Markets with a new price target

    The Benchmark Company initiated coverage of Forum Markets with a rating of Speculative Buy and set a new price target of $5.00

    4/7/26 8:46:27 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forum Markets Acquires Aircraft Engine for Approximately $12 Million, Advances Plan to Expand Aviation Portfolio to Five Engines

    Company Expects to Complete Acquisition of an Additional Engine in the Coming Weeks; Most Widely Used Engine Platform Offers Scale and Repeatable Deal Flow PALM BEACH, Fla., July 16, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today announced that it has closed on the acquisition of a commercial aircraft engine for approximately $12 million in cash, expanding the company's aviation portfolio to four income-generating engines under long-term lease to major U.S. airlines. Forum is in the process of finalizing the purchase of an a

    7/16/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Announces Initiation of Analyst Coverage by Sidoti & Company with $10.00 Price Target

    PALM BEACH, Fla., May 29, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today announced that Sidoti & Company, LLC has initiated coverage of the company's common stock with a Not Rated (NR) classification and a price target of $10.00 per share. Sidoti is the third research firm to initiate coverage of Forum in 2026. The research report, authored by Brendan McCarthy, CFA, was published on May 28, 2026. Sidoti's initiation highlights Forum's position as an early mo

    5/29/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum to Present at Benchmark's Digital Assets Summit on May 27

    PALM BEACH, Fla., May 19, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum"), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today announced that McAndrew Rudisill, chairman and CEO, and John Kristoff, senior vice president, corporate communications and investor relations, are expected to participate in the Benchmark Digital Assets Summit on Wednesday, May 27, 2026, in New York.  The company will participate in the panel discussion "How Tokenization Is Reshaping Private and Public Markets" at 3:00 PM EDT

    5/19/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lomashuk Konstantin sold $16,141 worth of shares (2,562 units at $6.30) (SEC Form 4)

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    7/20/26 9:26:28 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lomashuk Konstantin sold $20,846 worth of shares (3,387 units at $6.15) (SEC Form 4)

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    7/14/26 4:25:34 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lomashuk Konstantin sold $30,477 worth of shares (4,802 units at $6.35) (SEC Form 4)

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    7/9/26 4:44:25 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Leadership Updates

    Live Leadership Updates

    View All

    Forum Appoints Robert Spake as General Counsel

    PALM BEACH, Fla., March 3, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced the appointment of Robert Spake as the company's general counsel. Spake's deep legal expertise in capital markets, tokenization, and regulatory compliance strengthens Forum's leadership team and sharpens its focus on launching compliant, institutionally structured real-world asset products within evolving regulatory frameworks.  "Robert joins Forum at a pivotal mo

    3/3/26 9:00:00 AM ET
    $ETHZ
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Financials

    Live finance-specific insights

    View All

    Forum Markets Acquires Aircraft Engine for Approximately $12 Million, Advances Plan to Expand Aviation Portfolio to Five Engines

    Company Expects to Complete Acquisition of an Additional Engine in the Coming Weeks; Most Widely Used Engine Platform Offers Scale and Repeatable Deal Flow PALM BEACH, Fla., July 16, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today announced that it has closed on the acquisition of a commercial aircraft engine for approximately $12 million in cash, expanding the company's aviation portfolio to four income-generating engines under long-term lease to major U.S. airlines. Forum is in the process of finalizing the purchase of an a

    7/16/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Reports First Quarter 2026 Financial Results

    PALM BEACH, Fla., May 14, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets, today reported financial results for the first quarter ended March 31, 2026. "Forum continues to execute against our core strategy of building a platform centered on originating, structuring, and tokenizing institutional-grade, yield-generating assets," said McAndrew Rudisill, chairman and CEO. "We've expanded our origination capabilities with our entry into AI infr

    5/14/26 8:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Reports Fourth Quarter and Full Year 2025 Financial Results

    Company Introduces 2026 Guidance as RWA Tokenization Platform Begins to Scale PALM BEACH, Fla., March 31, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today reported financial results for the fourth quarter and full year ended December 31, 2025. "In less than a year, Forum has moved from concept to execution: from building the infrastructure, establishing key partnerships, and validating our technology, to generating revenu

    3/31/26 9:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care